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ethods. AAbstract Protein kinase B (PKB/Akt) regulates all aspects of cell growth, differentiation, and divi-
sion. PKB/Akt has recently garnered a great deal of attention as a promising molecular target for
cancer therapy due to its involvement in the development of several human cancers. In this study a
diverse set of 56 Akt1 inhibitors were aligned by three different methods (pharmacophore-, dock-
ing-based and rigid body alignment) for CoMFA, CoMSIA and HQSAR analysis. The best QSAR
models were obtained using rigid body alignment (Distill). CoMFA and CoMSIA models were
found statistically signiﬁcant with leave-one-out correlation coefﬁcient (q2) of 0.627 and 0.598,
respectively, cross validated coefﬁcient (r2cv) of 0.644 and 0.563, respectively, and conventional coef-
ﬁcient (r2) of 0.867 and 0.865, respectively. QSAR models were validated by a test set of 9 com-
pounds giving satisfactory predicted correlation coefﬁcient (r2pred) of 0.603 and 0.613 for CoMFA
and CoMSIA models, respectively. Leave-one-out correlation value (q2) of 0.687, r2pred of 0.742
and r2 of 0.868 were obtained for HQSAR analysis and found satisfactory. This study provides
valuable clues to design new compounds against PKB/Akt.
ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University.1. Introduction
Protein kinase B (PKB) also known as Akt, is a serine/threo-
nine kinase that belongs to the AGC family of kinases (Vivan-
co and Sawyers, 2002). Serine/threonine protein kinase is a key
enzyme in the phosphatidylinositol-3-kinase (PI3-K) cascade9624931060; fax: +91 2717
om, vivekvyas@nirmauni.ac.in
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tosis (Vyas et al., 2013). In mammals protein kinase B is com-
prised of three highly homologous isoforms, namely PKBa
(Akt1), PKBb (Akt2), and PKBc (Akt3) with a common struc-
ture made up of three domains: a PH domain at the N termi-
nus binds phosphatidylinositol-3,4,5 triphosphate (PI(3,4,5)P3)
and, is essential in the activation of the enzyme, a catalytic ki-
nase domain contains a classical kinase ATP-binding site and a
hydrophobic motif (HM) at the C terminus (Barile et al.,
2010). The activation of PKB by PI3K is antagonized by the
tumor suppressor phosphatase and tensin homolog (PTEN).
The increased PKB activity observed in most human tumors
could be the result of (a) increased PKB expression, (b) in-
creased PI3K activity, or (c) decreased PTEN activity (Scheid
and Woodgett, 2003). PKBs are over-expressed in a variety ofing Saud University.
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2 V.K. Vyas et al.human tumors, and at the genomic level, PKBa and PKBb
have been shown to be ampliﬁed in a number of cancer types.
PKB is known to phosphorylate over 20 substrates, many of
which are involved in the induction of apoptosis and in the ar-
rest of cell proliferation (Sarbassov et al., 2005). Three main
strategies can be applied to the development of novel PKB
inhibitors, targeting toward pleckstrin homology (PH) domain
(Mahadevan et al., 2008), ATP-binding kinase (Lindsley et al.,
2007), and hinge-region domain (Lindsley et al., 2005). En-
hanced PKB/Akt activity is the hallmark of several aggressive
malignancies, as a result, PKB/Akt has been considered as the
most promising target for the development of new anticancer
therapeutics (Collins, 2009). The present study was undertaken
to explore key structural requirements of different chemical
scaffolds as PKB/Akt inhibitors by utilizing comparative
molecular ﬁeld analysis (CoMFA), comparative molecular
similarity indices analysis (CoMSIA) and hologram quantita-
tive structure activity relationship (HQSAR) analysis with
three different (pharmacophore-, docking-based and rigid
body) alignment methods. CoMFA is a versatile and powerful
tool in rational drug design. CoMFA calculates steric and elec-
trostatic ﬁelds surrounding the molecules and correlating the
differences in these ﬁelds to inhibitory activity (Vyas and
Ghate, 2012). In CoMSIA analysis, similarity indices are cal-
culated at regularly placed grid points for aligned molecules.
CoMSIA calculates other molecular descriptors like hydro-
phobic ﬁelds, hydrogen-bond donor and acceptor ﬁelds (Singh
et al., 2012). Contour maps of CoMFA and CoMSIA ﬁelds de-
scribe the ‘favorable’ or ‘unfavorable’ contribution of a region
of interest surrounding the ligands to the target property. The
purpose of the HQSAR study is to explore individual atomic
contributions to molecular bioactivity with visual display of
active centers in a compound. Furthermore, HQSAR results
can be also somehow used as control to assess our CoMFA
and CoMSIA results. HQSAR technique does not require
molecular superposition (Sridhar et al., 2011). QSAR models
generated in this study would provide some new useful infor-
mation for designing new PKB inhibitors.
2. Materials and methods
2.1. Dataset
Available data from these literatures were used for the QSAR
study consisting of 56 compounds, obtained from same labora-
tory consisting of pyridine–pyrazolopyridine-based inhibitors
(12 compounds) (Zhu et al., 2007) and trans-3,40-bispyridinyl-
ethylenes (44 compounds) (Li et al., 2006). Akt1 IC50 values
were measured against Akt1 with ATP concentration of
10 lM employed similar experimental conditions and proce-
dures. The IC50 values (nM) were converted to pIC50 and sub-
sequently used as a dependent variable for 3D QSAR studies
(Table 1).
2.2. Selection of training and test sets
The total set of 56 inhibitors was divided into the training set
(47 compounds) for generating the QSAR model and a test set
(9 compounds) for validating the quality of the models. Selec-
tion of the training and test set molecules was done by consid-Please cite this article in press as: Vyas, V.K. et al., 3D QSAR an
using various alignment methods. Arabian Journal of Chemistryering the fact that test set molecules represent a range of
inhibitory activity similar to that of the training set. Thus,
the test set was the true representative of the training set. This
was achieved by arbitrarily setting aside 9 compounds as a test
set with regularly distributed biological data.
2.3. Computational details
QSAR modeling, calculations and visualizations for CoMFA,
CoMSIA and HQSAR analysis were performed using SYBYL
X 1.2 software from Tripos Inc., St. Louis, MO, USA. Com-
pound 8 was selected as the template molecule because of its
highest inhibitory activity. The structures of all other com-
pounds were constructed from the template molecule using
‘‘SKETCH’’ function in SYBYL and partial atomic charges
were calculated by the Gasteiger–Huckel method and energy
minimization was performed using the Tripos force ﬁeld
(Gasteiger and Marsili, 1980) with a distance-dependent dielec-
tric and Powell conjugate gradient algorithm. The minimum
gradient difference of 0.05 kcal/mol A˚ was set as a convergence
criterion (Clark et al., 1989).
2.4. Alignment
QSAR models are often sensitive to a particular alignment
scheme. Generally, the results depend upon the alignment
method of molecules. The comparisons of different alignment
techniques were reported (Roy et al., 2008) in the literature for
CoMFA and CoMSIA analysis. Therefore, three different
alignment techniques were compared carefully in this work,
in order to ﬁnd the most efﬁcient one for the present study.
2.4.1. Distill (align 1)
Rigid body alignment of molecules in a Mol2 database was
performed using maximum common substructure (MCS) de-
ﬁned by Distill. Compound 8 was used as a template and all
other compounds were aligned on the basis of the common
structure. MCS represents a common core of all the structures
used for the alignment. Distill generates MCS on the basic of
group of connected atoms common to a set of structures used
for the alignment. A rigid alignment attempts to align mole-
cules in a database to a template molecule on a common back-
bone or core (MCS). This core will typically have been
produced by Distill. The minimum atom count in MCS frag-
ments can be as small as 3. For the alignment of the molecules
using Distill, ﬁrst the core is looked for in all the molecules, if
the core may be found more than once, or there may be more
than one mapping of the core atoms to the molecule atoms. In
this case a single mapping is chosen. Finally, all the molecule
are ﬁt to the template using the best mapping of the core to
the molecules and the database is updated with the molecule’s
new orientation. Alignment of training and test set compounds
using the Distill module is shown in Fig. 1A.
2.4.2. Pharmacophore-based alignment (align 2)
All the compounds (training and test sets) were selected to gen-
erate the pharmacophore model using DISCOtech. All the
compounds were aligned on some common features depending
upon the position rotation and conformation. Generated phar-
macophore model contains 1 donor site, 1 acceptor atom and 2d HQSAR analysis of protein kinase B (PKB/Akt) inhibitors
(2013), http://dx.doi.org/10.1016/j.arabjc.2013.07.052
Table 1 Structures of PKB/Akt1 inhibitors with their actual activity.
N
R1 O R2
NH2
Compound R1 R2 Akt1 IC50 (nM)
a bpIC50
1
H
N
N
3-Indole 1.5 8.824
2
H
N
N
Cl
3-Indole 1.0 9.000
3
H
N
N
F3C
3-Indole 1.8 8.745
4
H
N
N NO2
3-Indole 953 6.021
5
H
N
N NH2
3-Indole 51 7.292
6
H
N
N NH2
Cl
3-Indole 7.1 8.149
7*
H
N
N N
3-Indole 0.6 9.222
8
H
N
N N
H3C
3-Indole 0.34 9.469
9
H
N
N N
Ph 223 6.652
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Table 1 (continued)
N
R1 O R2
NH2
Compound R1 R2 Akt1 IC50 (nM)
a bpIC50
10
H
N
N N
H3C
Ph 25 7.602
11
H
N
N N
Cl
Ph 59 7.229
12
H
N
N N+
H3C
O-
Ph 104 6.983
N
NR1 R2
O
R3
Compound R1 R2 R3 Akt1 IC50 (nM)
a bpIC50
13 Cl H
H2N
5290 5.277
14 H H
H2N
5080 5.294
15 H H
NH2
14710 4.832
16 H H
H2N
19320 4.714
17 H H
HN
10870 4.964
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Table 1 (continued)
N
R1 O R2
NH2
Compound R1 R2 Akt1 IC50 (nM)
a bpIC50
18 H H
HN
23910 4.621
19 H H
H2N
690 6.161
20 H H
H2N
6760 5.170
21 H H
H2N
8020 5.096
22 H H
H2N
O
4040 5.394
23 H H
H2N
OH
875 6.058
24 H H
H2N
CN
320 6.495
25 H H
H2N
324 6.489
26* H H
H2N
146 6.836
27 H H
H2N S
142 6.848
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Table 1 (continued)
N
R1 O R2
NH2
Compound R1 R2 Akt1 IC50 (nM)
a bpIC50
28 H H
H2N N
H
14 7.854
29 H H
H2N N
H
360 6.444
30 Cl H
H2N N
H
23 7.638
31 H Cl
H2N N
H
273 6.564
32* H H
H2N N
Me
500 6.301
33* H H
N
N
H
Me
Me
1100 5.959
34* H H
N
H
OH
24010 4.620
N
Ar1
A
R4
Compound Ar1 A R4 Akt1 IC50 (nM)
a bpIC50
35 NCl CH2
N
H
H2N
198 6.703
6 V.K. Vyas et al.
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Table 1 (continued)
N
R1 O R2
NH2
Compound R1 R2 Akt1 IC50 (nM)
a bpIC50
36
NCl NH
N
H
H2N
19 7.721
37*
NCl NH
N
H
H2N
H
79 7.102
38 N NH
N
H
H2N
H
9.7 8.013
39
N
NH
N
H
H2N
O 278 6.556
40
N
NH
H2N
O 3200 5.495
41 N NH
H2N
O 668 6.175
42
N
O
H
N Br
32250 4.491
43 N Bond
NH2
284 6.547
44
N
Bond
NH2
N
Me
760 6.119
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Table 1 (continued)
N
R1 O R2
NH2
Compound R1 R2 Akt1 IC50 (nM)
a bpIC50
45
N
O
N
H
H2N
23270 4.633
46
N
O
H2N
43010 4.366
N
X
O
NHNH2
Compound X Akt1 IC50 (nM)
a bpIC50
47* MeO 2670 5.573
48
O
6450 5.190
49 S 6350 5.197
50
S
3110 5.507
51 –NH2 121 6.917
52 MeNH– 176 6.754
53 EtNH– 163 6.788
54*
H
N
69 7.161
55*
N
H
147 6.833
56
N
3340 5.476
a Inhibitory activity against Akt1 with ATP concentration of 10 lM.
b Negative logarithm of IC50 (nM).
* Test set.
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Table 2 Statistical parameters of the comparative study of three alignments using the CoMFA and CoMSIA models by PLS analysis.
Statistical parameters Align 1 (rigid body) Align 2 (pharmacophore-based) Align 3 (docking-based)
CoMFA CoMSIA HQSAR CoMFA CoMSIA HQSAR CoMFA CoMSIA HQSAR
q2 0.627 0.598 0.687 0.364 0.208 0.451 0.303 0.415 0.446
r2ncv 0.867 0.865 0.868 0.880 0.847 0.537 0.752 0.806 0.732
r2cv 0.644 0.563 0.210 0.288 0.268 0.206
r2bs 0.945 0.932 0.915 0.918 0.861 0.913
N 6 6 3 6 4 3 3 2 2
F 1511 1258 352 281 46 147
SEE 0.067 0.074 0.048 0.195 0.304 0.238 0.665 0.410 0.318
r2pred 0.603 0.613 0.742 0.414 0.511 0.655 0.232 0.423 0.623
Probability of r2ncv 0.0 0.0 0.0 0.0 0.0 0.0
Field contribution
Steric 0.544 0.154 0.551 0.148 0.391 0.105
Electrostatic 0.456 0.183 0.449 0.176 0.609 0.219
Hydrophobic 0.236 0.198 0.202
H-bond donor 0.235 0.202 0.237
H-bond acceptor 0.193 0.276 0.237
N is the optimal number of components (PLS components); q2 is the leave-one-out (LOO) validation coefﬁcient; r2cv is cross-validation
coefﬁcient; r2ncv is the non-cross-validation coefﬁcient; r
2
pred is the predictive correlation coefﬁcient; SEE is the standard error of estimation; F is
the F-test value; r2bs is mean r
2 of bootstrapping analysis (100 runs).
3D QSAR and HQSAR analysis of protein kinase B (PKB/Akt) inhibitors using various alignment methods 9hydrophobic regions, which were then used for the alignment
of the compounds in QSAR studies (Fig. 1B).
2.4.3. Docking-based alignment (align 3)
The active conformation of all the compounds was achieved by
molecular docking studies. Docking experiments were per-
formed using Surﬂex–Dock module of SYBYL X 1.3. The
X-ray crystallographic structure of PKB (PDB ID: 2ZDO)
(Davies et al., 2007) solved at 1.8 A˚ resolution was retrieved
from the PDB databank. Each inhibitor was docked into the
ALK using the ﬂexible docking module implemented in Sur-
ﬂex–Dock (Jain, 1996). Active conformation was selected from
the binding orientation in the active site of ALK and evaluated
by consideration of binding free energy scores (Surﬂex–Dock
score). Since for all compounds the best-docked geometries
(active conformation) were in agreement with the crystallo-
graphic data of the PKB complex (and thus already aligned)
(Fig. 1C), they were directly submitted to QSAR studies.
These three different alignment methods of molecules
yielded very good statistical results, but rigid body alignment
of molecules by Distill (align 1) gave us the best results (Ta-
ble 2) with a signiﬁcant statistical value of q2 and r2cv as com-
pared to align 2 and 3, so further QSAR studies was carried
out using align 1 (Distill).
2.5. CoMFA model
In CoMFA analysis, steric and electrostatic potential energies
were calculated using the Tripos force ﬁeld with a probe atom
having a van der waals radius of sp3-hybridized carbon and
a + 1 charge to generate steric (Lennard–Jones 6–12 potential)
ﬁeld energies and electrostatic (Coulombic potential) ﬁelds
with a distance-dependent dielectric at each lattice point. A lat-
tice with 2 A˚ grid spacing extending at least 4 A˚ in each direc-
tion beyond the aligned molecules was used. The steric and
electrostatic energy values were truncated at 30.0 kcal/mol.Please cite this article in press as: Vyas, V.K. et al., 3D QSAR an
using various alignment methods. Arabian Journal of ChemistryIn order to reduce noise and improve efﬁciency, column ﬁlter-
ing (minimum sigma) was set to 2.0 kcal/mol.
2.6. CoMSIA model
The CoMSIA similarity index descriptors were calculated
using a dummy sp3-hybridized carbon with +1 charge. The
same lattice box used in CoMFA calculations was also applied
to CoMSIA calculations with a grid spacing of 2 A˚ with a ra-
dius of 1.0 A˚ as implemented in SYBYL. Similarity indices
were calculated between a probe and each atom of the mole-
cules based on a Gaussian distance function. CoMSIA not
only computes steric and electrostatic ﬁelds, but also calculates
hydrophobic, hydrogen-bond donor (HBD), and hydrogen-
bond acceptor (HBA) ﬁelds. For the distance dependence be-
tween the probe atom and the molecule atoms, a Gaussian
function was used. Because of the different shape of the Gauss-
ian function, the similarity indices calculated at all grid points,
both inside and outside the molecular surface.
2.7. Hologram QSAR (HQSAR)
HQSAR is a technique based on the concept of using molecu-
lar substructures expressed in a binary pattern (molecular
hologram) as descriptors in QSAR models. The premise of
HQSAR is that the two-dimensional (2D) ﬁngerprint encodes
the structure of a molecule, which is a key determinant of all
molecular properties (Kulkarni et al., 2008). 2D chemical data-
base storage and searching technologies rely on linear nota-
tions that deﬁne chemical structures (WLN–Wiswesser line-
formula notation; SMILES–simpliﬁed molecular input line en-
try system; SLN–SYBYL line notation). The process involves
the generation of fragments that are hashed into array bins in
the range of 1 to L (length) wherein the array is called molec-
ular hologram and the bin occupancies are the descriptor vari-
ables. In this study, ﬁngerprints were generated for alld HQSAR analysis of protein kinase B (PKB/Akt) inhibitors
(2013), http://dx.doi.org/10.1016/j.arabjc.2013.07.052
Table 3 Experimental and predicted pIC50 with residuals of the training and test sets using CoMFA and CoMSIA models (align 1).
Compound Experimental pIC50 Predicted pIC50 Residual
CoMFA CoMSIA HQSAR CoMFA CoMSIA HQSAR
1 8.824 8.804 8.884 9.114 0.02 0.06 0.29
2 9.000 9.140 8.980 9.080 0.14 0.02 0.08
3 8.745 8.735 8.755 9.025 0.01 0.01 0.28
4 6.021 6.011 5.981 5.311 0.01 0.04 0.71
5 7.292 7.192 7.332 6.682 0.10 0.04 0.61
6 8.149 8.149 8.079 8.409 0.00 0.07 0.26
7* 9.222 11.232 11.012 9.462 2.01 1.79 0.24
8 9.469 9.499 9.459 9.649 0.03 0.01 0.18
9 6.652 6.572 6.582 5.742 0.08 0.07 0.91
10 7.602 7.682 7.692 7.332 0.08 0.09 0.27
11 7.229 7.129 7.199 6.719 0.10 0.03 0.51
12 6.983 7.013 6.983 7.473 0.03 0.00 0.49
13 5.277 5.097 5.117 5.437 0.18 0.16 0.16
14 5.294 5.444 5.464 5.774 0.15 0.17 0.48
15 4.832 4.852 4.872 4.622 0.02 0.04 0.21
16 4.714 4.714 4.714 4.704 0.00 0.00 0.01
17 4.964 4.944 4.974 4.674 0.02 0.01 0.29
18 4.621 4.701 4.631 4.491 0.08 0.01 0.13
19 6.161 6.241 6.131 5.491 0.08 0.03 0.67
20 5.170 5.180 5.160 4.370 0.01 0.01 0.80
21 5.096 5.046 5.116 4.526 0.05 0.02 0.57
22 5.394 5.434 5.374 4.494 0.04 0.02 0.90
23 6.058 6.078 6.078 6.628 0.02 0.02 0.57
24 6.495 6.495 6.445 5.645 0.00 0.05 0.85
25 6.489 6.519 6.519 5.919 0.03 0.03 0.57
26* 6.836 7.666 7.706 6.646 0.83 0.87 0.19
27 6.848 6.768 6.758 7.188 0.08 0.09 0.34
28 7.854 7.784 7.794 8.764 0.07 0.06 0.91
29 6.444 6.434 6.424 7.054 0.01 0.02 0.61
30 7.638 7.678 7.688 7.778 0.04 0.05 0.14
31 6.564 6.574 6.594 6.674 0.01 0.03 0.11
32* 6.301 7.781 8.381 6.641 1.48 2.08 0.34
33* 5.959 8.009 7.469 6.469 2.05 1.51 0.51
34* 4.620 4.580 5.260 5.050 0.04 0.64 0.43
35 6.703 6.663 6.723 7.253 0.04 0.02 0.55
36 7.721 7.741 7.761 7.671 0.02 0.04 0.05
37* 7.102 5.712 5.632 6.702 1.39 1.47 0.40
38 8.013 8.043 7.983 8.533 0.03 0.03 0.52
39 6.556 6.496 6.526 7.006 0.06 0.03 0.45
40 5.495 5.535 5.505 6.325 0.04 0.01 0.83
41 6.175 6.145 6.145 7.065 0.03 0.03 0.89
42 4.491 4.501 4.491 4.921 0.01 0.00 0.43
43 6.547 6.587 6.577 6.357 0.04 0.03 0.19
44 6.119 6.159 6.129 6.639 0.04 0.01 0.52
45 4.633 4.603 4.623 4.143 0.03 0.01 0.49
46 4.366 4.336 4.406 4.476 0.03 0.04 0.11
47* 5.573 6.393 6.133 5.973 0.82 0.56 0.40
48 5.190 5.140 5.030 4.810 0.05 0.16 0.38
49 5.197 5.177 5.197 4.947 0.02 0.00 0.25
50 5.507 5.507 5.737 5.067 0.00 0.23 0.44
51 6.917 6.857 6.857 6.017 0.06 0.06 0.90
52 6.754 6.814 6.804 5.904 0.06 0.05 0.85
53 6.788 6.788 6.798 6.128 0.00 0.01 0.66
54* 7.161 8.721 8.591 7.941 1.56 1.43 0.78
55* 6.833 7.493 7.603 7.423 0.66 0.77 0.59
56 5.476 5.506 5.476 6.096 0.03 0.00 0.62
* Test set compounds.
10 V.K. Vyas et al.substructures between four and seven atoms in size for all mol-
ecules. The substructure ﬁngerprints were then hashed into
hologram bins with lengths of 97, 151, 199, 257, 307 andPlease cite this article in press as: Vyas, V.K. et al., 3D QSAR an
using various alignment methods. Arabian Journal of Chemistry353. Leave-one-out (LOO) and cross-validation (CV) methods
were applied to determine the number of components that
yield a good predictive model.d HQSAR analysis of protein kinase B (PKB/Akt) inhibitors
(2013), http://dx.doi.org/10.1016/j.arabjc.2013.07.052
Figure 2 Plot of experimental versus predicted activity of
training and test set compounds based on (A) CoMFA model,
(B) CoMSIA model, (C) HQSAR model.
3D QSAR and HQSAR analysis of protein kinase B (PKB/Akt) inhibitors using various alignment methods 112.8. Partial least square (PLS) analysis
CoMFA, CoMSIA and HQSAR models were derived using
PLS regression analysis. Calculated CoMFA and CoMSIA
descriptors were used as independent variables and PKB
inhibitory activity (pIC50) as the dependent variables in the
PLS analysis. In HQSAR, PLS analysis yields a mathematical
equation that related the molecular hologram bin values to
the inhibition activity of the compounds in the database
(Honorio et al., 2005). PLS analysis was performed using
the leave-one-out (LOO) and cross-validation (CV) methods
for 3D and HQSAR analysis, which gives q2 and r2cv, respec-
tively as a statistical index of predictive power. The non
cross-validated models were assessed by the conventional cor-
relation coefﬁcient (r2), standard error of estimation (SEE)
and F values. A 100-cycle bootstrap analysis was performed
to assess the statistical conﬁdence of the derived models.
The mean correlation coefﬁcient is represented as bootstrap
r2 (r2boot). The PLS analysis was then repeated with no valida-
tion using the optimal number of components to generate
CoMFA, CoMSIA and HQSAR models (Cramer III et al.,
1988).
2.9. Predictive r2 value
The predictive r2 (r2pred) was based only on the molecules (9
compounds) not included in the training set and is deﬁned as
r2pred = SD-PRESS/SD where, SD is the sum of the squared
deviations between the inhibitory activity of molecules in a test
set and the mean inhibitory activity of a training set molecules,
and PRESS is the sum of squared deviations between predicted
and actual activity values for every molecule in a test set.
3. Results and discussion
3.1. Results of the CoMFA analysis
The statistical parameters of standard CoMFA models con-
structed with steric and electrostatic ﬁelds are given in Table 2.
The q2, r2cv, r
2
pred, r
2
ncv, F and SEE values were computed as de-
ﬁned in SYBYL. PLS analysis showed a q2 value of 0.627 and
r2cv of 0.644. A non-cross-validated PLS analysis results in a
conventional r2 of 0.867, F= 1511 and a standard error of
estimation (SEE) of 0.067. In both steric and electrostatic ﬁeld
contributions, former accounts for 0.544, while the latter con-Figure 1 Alignment of training and test set compounds (A) rigid bod
based.
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slightly higher to the binding afﬁnity. A high bootstrapped r2
(0.945) value and low standard deviation (0.004) suggest a high
degree of conﬁdence in the analysis. The predicted and exper-
imental pIC50 and residual values are listed in Table 3, and the
correlation between the predicted and the experimental pIC50
of training and test set is depicted in Fig. 2A.
3.2. Results of the CoMSIA analysis
CoMSIA offered steric, electrostatic, hydrophobic, HBD and
HBA ﬁelds’ information. CoMSIA models were generatedy alignment using Distill, (B) pharmacophore-based (C) docking-
d HQSAR analysis of protein kinase B (PKB/Akt) inhibitors
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CoMSIA models showed higher correlation and high predic-
tive properties. We found that the CoMSIA descriptors such
as steric, electrostatic, hydrophobic, and HBD ﬁelds played a
signiﬁcant role in the prediction of inhibitory activity. These
factors result in best CoMSIA models. Statistically signiﬁcant
CoMSIA model gives q2 of 0.598, r2cv of 0.563, r
2 of 0.865, F of
1258 and SEE of 0.074 values with 6 components. The corre-
sponding ﬁeld contributions are 0.154 (steric), 0.183 (electrost-
stic), 0.236 (hydrophobic), 0.235 (HBD) and 0.193 (HBA). Plot
of experimental and predicted pIC50 of training and test sets is
depicted in Fig. 2B.
3.3. Results of the HQSAR analysis
As per HQSAR calculations, the lowest SEE of 0.048 occurred
at a cross-validated q2 of 0.687 with 3 components. The holo-
gram result with the lowest SEE has a hologram length of 353.
The PLS analysis gave a conventional r2 of 0.868 for all the
studied compounds.
3.4. Predictive power of CoMFA, CoMSIA and HQSAR models
The predictive abilities of QSAR models were further validated
using a test set of 9 compounds, not included in the model gen-
eration study. The predicted r2 (r2pred) values of CoMFA, CoM-
SIA and HQSAR models are 0.603, 0.613 and 0.742,
respectively (Table 2). By comparison of experimental and pre-
dicted pIC50 values of a test set of compounds, it is observed
that CoMFA, CoMSIA and HQSAR models performed well
in the predication of inhibitory activity.Figure 3 CoMFA (std*coeff) contour maps. Compound 8 is shown
green (80% contribution) refer to sterically favored regions; yellow (2
CoMFA electrostatic ﬁeld. Electrostatic contour map shown in red
substituents are favored and blue contours (80% contribution) refer t
Please cite this article in press as: Vyas, V.K. et al., 3D QSAR an
using various alignment methods. Arabian Journal of Chemistry3.5. CoMFA contour maps
The CoMFA and CoMSIA contour maps are more or less sim-
ilar and both models established good predictive ability. Com-
pound 8 is shown inside the ﬁeld for demonstrating contours
generated from CoMFA and CoMSIA analysis. favored and
disfavored levels ﬁxed at 80% and 20%, respectively. In the
CoMFA steric contour map (Fig. 3A) reference molecule’s
(8) 3-methyl group substituted on the pyrazolo[3,4-c]pyridine
ring was observed in the region of green colored (80% contri-
bution) contour, which showed favorable bulky substitution.
Differences in the activity of 8 and 7 (8, IC50 = 0.34 nM,
7= 0.6 nM) were due to the presence of the more sterically fa-
vored 3-methyl group in 8. Similar could be the reason for
activity diversity in molecules 10 (IC50 = 25 nM) and 11
(IC50 = 59 nM). In the case of inactive molecules, the exten-
sion of various groups led to the loss of inhibitory activity as
they were oriented away from the green contour map as in
the case of molecules 9 (IC50 = 223 nM) and 4
(IC50 = 953 nM). A second favorable steric contour was
found at the methylene spacer in between pyridine and 3-in-
dole ring system indicating a favorable effect of steric bulk.
The bulky/steric unfavorable yellow colored (20% contribu-
tion) region ﬂanked near the pyrazolo[3,4-c]pyridine ring sys-
tem showed the sterically disfavored point. Unsubstituted
pyrazolo[3,4-c]pyridine ring in compound 1 showed better
activity (IC50 = 1.5 nM) as compared to sterically favored (–
CF3) substituted pyrazolo[3,4-c]pyridine in compound 3
(IC50 = 1.8 nM). A second unfavorable yellow region ﬂanked
near the propan-2-amine bridge suggested that there is a deﬁ-
nite structural requirement of a substructure with appropriate
shape to exhibit good inhibitory activity. The CoMFA electro-inside the ﬁeld, (A) contour maps of CoMFA steric map shown in
0% contribution) indicates disfavored areas, (B) contour maps of
(20% contribution) indicates regions where negatively charged
o regions where negatively charged substituents are disfavored.
d HQSAR analysis of protein kinase B (PKB/Akt) inhibitors
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Figure 4 CoMSIA (std*coeff) contour maps. Compound 8 is
shown inside the ﬁeld. Hydrophobic ﬁeld (A), HBD ﬁeld (B), and
HBA ﬁeld (C). Yellow and gray contours indicate regions where
hydrophobic groups favored and disfavored the activity, respec-
tively. Cyan contours represent areas where HBD is favored.
Magenta and red contours represent areas where HBA is favored
and disfavored, respectively. Favored and disfavored levels are
ﬁxed at 80% and 20%, respectively.
3D QSAR and HQSAR analysis of protein kinase B (PKB/Akt) inhibitors using various alignment methods 13static contour map is shown in Fig. 3B. A large blue colored
(80% contribution) contour was observed around the indole
ring and indicated that electropositive groups in this region
would increase the activity. For example, compound 10
(IC50 = 25 nM) had a phenyl ring in this region and exhibits
good activity as compared to compound 4 (IC50 = 953 nM),
which has an indole ring in this region. The electrostatic con-
tour map displays three red colored polyhedrons (20% contri-
bution). A large red colored contour close to the 2-amine
group suggested that electronegative groups at this position
would increase the activity. A small red colored contour was
very close to negatively charged oxygen atom of propan-2-
amine linker, which is necessary for a red colored favorable
isopleth in proximity to this area. Oxygen atom in such a posi-Please cite this article in press as: Vyas, V.K. et al., 3D QSAR an
using various alignment methods. Arabian Journal of Chemistrytion usually can form H-bonds with amino acid residues of the
binding site of PKB/Akt. Similar could be the reason for di-
verse activity in molecules 8 (IC50 = 0.34 nM) and 35
(IC50 = 198 nM). A small red colored contour at the methy-
lene spacer indicated that the presence of electronegative sub-
stituents is for good activity.
3.6. CoMSIA contour maps
CoMSIA contribution maps denote those areas within the
speciﬁed region where the presence of a group with a particular
physicochemical property will be favored or disfavoured for
good inhibitory activity. CoMSIA calculates both steric and
electrostatic ﬁelds, as in CoMFA, but additionally uses hydro-
phobic, HBD and HBA ﬁelds. favored and disfavored levels
ﬁxed at 80% and 20%, respectively The CoMSIA hydrophobic
contour map is shown in Fig. 4A, represented by yellow (80%
contribution) and gray (20% contribution) colored contours.
Yellow colored contours indicated the regions where hydro-
phobic groups on ligands are favored and gray colored con-
tours represent those areas where hydrophobic groups are
unfavored (or favorable for hydrophilic groups on ligands).
One large yellow colored polyhedral is observed near the in-
dole ring indicating that the hydrophobic property in this re-
gion would increase the activity. It can be observed by
comparing the structures of 10 (25 nM) and 5 (51 nM), 5 con-
tains the indole ring which is less hydrophobic than the phenyl
ring of 10 in this region. Second small yellow colored region
was observed near the 3-methyl group substituted on the pyr-
azolo[3,4-c]pyridine ring system suggesting that hydrophobic
groups in this region favor Akt1 inhibitory activity. Difference
in the activity of 3 and 4 (3, IC50 = 1.8 nM, 4= 953 nM) was
due to the presence of a more sterically favored –CF3 group in
3. A yellow colored contour in this region of the hydrophobic
map was in agreement with the green colored contour of the
steric map. A large gray colored contour is observed near
the pyrazolo[3,4-c]pyridine ring, indicating that the hydro-
philic group in this region would increase the activity. This
can be explained be comparing structure and activity of com-
pound 1 (IC50 = 1.5 nM) and 6 (IC50 = 7.1 nM). A second
small gray colored contour was observed near the propan-2-
amine bridge, illustrated that adding the hydrophobic group
at this position would decrease the activity. The graphical
interpretation of the HBD interactions in the CoMSIA model
is represented in Fig. 4B. Cyan colored contours (80% contri-
bution) indicated the regions where HBD substituents on li-
gands are favored and purple colored contours (20%
contribution) represent those areas where HBD properties on
compounds are disfavored. In the HBD contour map, three
cyan colored areas were observed; one was observed away
from the molecules area and indicated that there is no signiﬁ-
cance of HBD in this region, and the other two were observed
near the pyrazolo[3,4-c]pyridine ring, especially one at the pro-
tonated –N atom of the pyrazolo ring, suggesting a favorable
H-bonding between the active site amino acid and –N atom. It
is indeed in case of compound 2 (IC50 = 1.0 nM) and 40
(IC50 = 3200 nM). A large purple colored region was observed
near the propan-2-amine bridge and a small purple colored
contour observed at –N atom of pyridine ring indicated that
HBD properties in this region would disfavoured the activity.
The graphical interpretation of the HBA interactions in thed HQSAR analysis of protein kinase B (PKB/Akt) inhibitors
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14 V.K. Vyas et al.CoMSIA model is shown in Fig. 4C. Magenta colored (80%
contribution) and red colored (20% contribution) contours
represented the area where HBA are favored and disfavored,
respectively. Two magenta colored contours and red colored
contours were in complex with each other and an overlap of
contours occurred near the indole ring system which is very
complex to interpret. Analysis of CoMFA and CoMSIA con-
tour plots offered enough information to understand the
importance of substituents at a particular position for better
activity.
4. Conclusions
PKB/Akt has emerged as an attractive target for the develop-
ment of novel anticancer therapeutics. In this study, we de-
scribed 3D QSAR and HQSAR analysis as a rational
strategy for the design of novel PKB inhibitors, using three dif-
ferent alignment methods. All the models (CoMFA, CoMSIA
and HQSAR) were found satisfactory according to the statis-
tical parameters. CoMFA and CoMSIA models are satisfac-
tory according to the statistical results as well as the contour
maps analysis. The present QSAR approach provides useful
information to design novel derivatives with higher selectivity
and efﬁcacy for PKB/Akt inhibition.Acknowledgments
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